Freeline to Participate in Stifel 2021 Virtual Healthcare Conference
Freeline Therapeutics Holdings plc (Nasdaq: FRLN) will participate in the Stifel 2021 Virtual Healthcare Conference on November 15, 2021, at 1:20 p.m. ET. CEO Michael Parini is scheduled for a Fireside Chat. A webcast of this event will be available for 90 days on the Freeline website. Additionally, senior management will hold virtual one-on-one meetings with investors on November 16. Freeline focuses on developing AAV-mediated gene therapies for inherited debilitating diseases, with programs targeting Hemophilia B and Fabry disease.
- None.
- None.
LONDON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that the Company will participate in the Stifel 2021 Virtual Healthcare Conference. Freeline Chief Executive Officer Michael Parini is scheduled to participate in a Fireside Chat at the event on November 15, 2021 at 1:20 p.m. ET.
A webcast of the Fireside Chat will be available on the Investors section of the Freeline website for 90 days. Senior management will participate in virtual one-on-one meetings with investors at the conference on November 16.
About Freeline Therapeutics
Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (“AAV”) vector-mediated systemic gene therapies. The Company is dedicated to improving patient lives through innovative, one-time treatments that provide functional cures for inherited systemic debilitating diseases. Freeline uses its proprietary, rationally-designed AAV vector, along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into the patient’s bloodstream. The Company’s integrated gene therapy platform includes in-house capabilities in research, clinical development, manufacturing and commercialization. The Company has clinical programs in Hemophilia B and Fabry disease, as well as preclinical programs in Gaucher disease Type 1 and Hemophilia A. Freeline is headquartered in the UK and has operations in Germany and the US.
Contact
David S. Arrington
Vice President Investor Relations & Corporate Communications
Freeline Therapeutics
david.arrington@freeline.life
+1 (646) 668 6947
FAQ
When will Freeline Therapeutics participate in the Stifel 2021 Virtual Healthcare Conference?
Who is scheduled to speak at the Stifel 2021 Virtual Healthcare Conference for Freeline Therapeutics?
What time is the Fireside Chat for Freeline Therapeutics at the conference?
Will there be a recording of the Fireside Chat available?
What are the main therapeutic areas Freeline Therapeutics focuses on?
